



1617

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gosse B. Bruinsma

Serial No.: 10/593,179

Filed: October 4, 2006 (presumed)

For: METHOD OF TREATING DOWN

SYNDROME

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 3154-6272.1US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandrai, VA 22313-1450.

October 10, 2006

Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

Foreign Patent Documents

Document No.

Publication Date

Patentee

WO 03/082270 A1

10-09-2003

Axonyx, Inc.

Serial No.: 10/593,179

Other Documents

Cure Research for Alzheimer's Disease, (visited 1/7/2004) http://www.wrongdiagnosis.com/a/alzheimers_disease/research.htm.

PRASHER et al., A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--Pilot Study, International Journal of Geriatric Psychiatry, 2002, pp. 270-78, Vol. 17.

SHAW et al., Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development, PNAS, June 19, 2001, pp. 7605-10, Vol. 98, No. 13.

PATEL et al., Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor, Jan. 1998, pp. 171-76, Vol. 9, No. 1.

This Supplemental Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,

Allen C. Turner

Registration No. 33,041 Attorney for Applicant

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: October 10, 2006

ACT/bv

Enclosures: Form PTO/SB/08

Cited Non-U.S. Patent Documents

Document in ProLaw

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/593,179

Filing Date October 4, 2006 (presumed)

First Named Inventor Gosse B. Bruinsma

Group Art Unit To be assigned

Examiner Name To be assigned

Attorney Docket Number 3154-6272.1US

(use as many sheets as necessary)
Sheet 1 of 2

	Document Number	U.S. PATENT D Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
xalfiaer Cite	Number - Kind Code ² (if known)			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	US-				
	US				
	US-				
	US- US-				
	US-				
	US-				
	US-	The state of the s			
	US-	The state of the s			
	US-	3345			
	US-				
	US-		***************************************		
	US-		***************************************		
	US-				
	US-			<u> </u>	
	US-			The state of the s	
	US-			The state of the s	
	US-			- The state of the	
	US-			**************************************	
	US-				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6		
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY					
/R.H./		WO 03/082270 A1	10-09-2003	Axonyx, Inc.				
	<u> </u>		-					
	 							
	l .		i I					

Examiner Signature /Raymond Henley III/ Date Considered 07/10/2009	
--	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Substitute for form 1449A/PTO				Complete if Known		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/593,179	
					Filing Date	October 4, 2006 (presumed)	
					First Named Inventor	Gosse B. Bruinsma	
					Group Art Unit	To be assigned	
	(use as many sheets as necessary)				Examiner Name	To be assigned	
	Sheet	2	of	2	Attorney Docket Number	3154-6272.1US	

	ı	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	, ((o o o o o o o o o o o o o o o o o					
/R.H./		Cure Research for Alzheimer's Disease, (visited 1/7/2004) http://www.wrongdiagnosis.com/a/alzheimers_disease/research.htm .				
/R.H./		PRASHER et al., A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease-Pilot Study, International Journal of Geriatric Psychiatry, 2002, pp. 270-78, Vol. 17.				
R.H./		SHAW et al., Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development, PNAS, June 19, 2001, pp. 7605-10, Vol. 98, No. 13.				
/R.H./		PATEL et al., Abstract, Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor, Jan. 1998, pp. 171-76, Vol. 9, No. 1.				
_						
<u></u>	<u> </u>					

			1	
Examiner	/Raymond Henley lii/	Date	07/10/2009	
Signature	/raymond ramey m/	Considered	0771072000	.]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.